Clarivate (NYSE:CLVT) Shares Up 6.7% – Still a Buy?

Clarivate PLC (NYSE:CLVT) was up 6.7% during mid-day trading on Monday . The stock traded as high as $2.92 and last traded at $2.9760. Approximately 224,744 shares were traded during trading, a decline of 97% from the average daily volume of 6,817,749 shares. The stock had previously closed at $2.79.

Wall Street Analyst Weigh In

Several analysts recently issued reports on CLVT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Clarivate in a report on Friday, March 27th. Citigroup reduced their price target on shares of Clarivate from $4.25 to $2.80 and set a “neutral” rating for the company in a report on Wednesday, March 4th. The Goldman Sachs Group cut shares of Clarivate from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $4.20 to $3.60 in a research note on Thursday, January 8th. Wall Street Zen upgraded shares of Clarivate from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Royal Bank Of Canada dropped their price objective on shares of Clarivate from $5.00 to $3.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 25th. Five investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $3.22.

Clarivate Stock Up 3.0%

The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -13.69 and a beta of 1.41. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.84 and a current ratio of 0.84. The business’s 50-day moving average is $2.47 and its 200-day moving average is $2.94.

Clarivate (NYSE:CLVT) last announced its earnings results on Wednesday, April 29th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. The business had revenue of $585.50 million during the quarter, compared to analysts’ expectations of $569.50 million. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter last year, the company posted $0.14 EPS. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. On average, equities analysts predict that Clarivate PLC will post 0.63 EPS for the current year.

Institutional Investors Weigh In On Clarivate

A number of hedge funds have recently made changes to their positions in the company. American Century Companies Inc. raised its stake in shares of Clarivate by 20.6% in the third quarter. American Century Companies Inc. now owns 9,973,797 shares of the company’s stock worth $38,200,000 after acquiring an additional 1,706,306 shares during the last quarter. Iridian Asset Management LLC CT raised its stake in shares of Clarivate by 52.4% in the fourth quarter. Iridian Asset Management LLC CT now owns 1,528,410 shares of the company’s stock worth $5,105,000 after acquiring an additional 525,452 shares during the last quarter. Cove Street Capital LLC raised its stake in shares of Clarivate by 4,075.2% in the third quarter. Cove Street Capital LLC now owns 452,462 shares of the company’s stock worth $1,733,000 after acquiring an additional 441,625 shares during the last quarter. LSV Asset Management bought a new position in shares of Clarivate in the third quarter worth about $8,072,000. Finally, Sequoia Financial Advisors LLC raised its stake in shares of Clarivate by 75.6% in the fourth quarter. Sequoia Financial Advisors LLC now owns 30,563 shares of the company’s stock worth $102,000 after acquiring an additional 13,161 shares during the last quarter. Institutional investors and hedge funds own 85.72% of the company’s stock.

About Clarivate

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.